May 13, 2024 07:39 AM EDTUpdated 01:20 PM
R&D

Mer­ck winds down Phase 3 TIG­IT/PD-1 com­bo study due to safe­ty-re­lat­ed dropouts

Ayisha Sharma

News Reporter

A large num­ber of pa­tient dropouts caused by im­mune side ef­fects have forced Mer­ck to end a late-stage tri­al of its an­ti-TIG­IT drug vi­bostolimab in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times